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Context: The I148M (rs738409-G) variant in PNPLA3 increases liver fat content but may be protective 
against cardiovascular disease. Insulin resistance (IR) amplifies the effect of PNPLA3-I148M on liver 
fat. 
Objective: To study whether PNPLA3-I148M confers an antihyperlipidemic effect in insulin-resistant 
patients. 
Design: Cross-sectional study comparing the impact of PNPLA3-I148M on plasma lipids and 
lipoproteins in two cohorts, both divided into groups based on rs738409-G allele carrier status and 
median HOMA-IR. 
Setting: Tertiary referral center. 
Patients: 298 obese patients who underwent a liver biopsy during bariatric surgery (Bariatric cohort; 
age 49±9 years, BMI 43.2±6.8 kg/m2), and 345 less obese volunteers in whom liver fat was measured 
by proton magnetic resonance spectroscopy (Non-bariatric cohort; age 45±14 years, BMI 29.7±5.7 
kg/m2). 
Main Outcome Measures: Nuclear magnetic resonance profiling of plasma lipids, lipoprotein particle 
subclasses and their composition. 
Results: In both cohorts, individuals carrying the PNPLA3-I148M variant had significantly higher liver 
fat content than non-carriers. In insulin-resistant and homozygous carriers, PNPLA3-I148M exerted a 
distinct antihyperlipidemic effect with decreased very-low-density lipoprotein (VLDL) and low-density 
lipoprotein particles (LDL) and their constituents, and increased high-density lipoprotein particles and 
their constituents, as compared to non-carriers. VLDL particles were smaller and LDL particles larger 
in PNPLA3-I148M carriers. These changes were geometrically opposite to those due to IR. PNPLA3-
I148M did not have a measurable effect in patients with lower IR, and its effect was smaller albeit 
still significant in the less obese compared to the obese cohort. 
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Cardiovascular disease (CVD) is the leading cause of death in patients with nonalcoholic fatty liver 
disease (NAFLD) (1), which usually coexists with the metabolic/insulin resistance (IR) syndrome (2). 
In this “Metabolic NAFLD”, IR impairs the ability of insulin to suppress hepatic production of glucose 
and triglyceride (TG)-rich very-low-density lipoprotein (VLDL) particles (2), manifesting clinically as 
hyperglycemia and atherogenic dyslipidemia (3). The increased risk of CVD in NAFLD is considered to 
be the consequence of atherogenic dyslipidemia, rather than of steatosis itself (4). However, NAFLD 
is heterogenous and not uniformly associated with dyslipidemia and an increased risk of CVD. The 
best example of this is NAFLD caused by the E167K (rs58542926-T) gene variant in transmembrane 
6 superfamily member 2 (TM6SF2), which decreases plasma TG (5-8), cholesterol (8-10) and apoB 
(7,11) concentrations and the risk of myocardial infarction (9), cardiovascular events and 
atherosclerotic plaques (7). 
 
The I148M variant (rs738409, c.444C>G) in patatin-like phospholipase domain containing 3 (PNPLA3) 
is common (prevalence 30-50% worldwide (12,13)) and the most important genetic risk factor for 
NAFLD. It significantly increases liver fat content (i.e. intrahepatic triglycerides [IHTGs]) and 
predisposes variant carriers to advanced liver disease (14,15), while simultaneously dissociating the 
NAFLD-phenotype from IR (14,16). Consistent with this dissociation, large-scale genomic studies have 
associated the PNPLA3-I148M variant with a lower risk of CVD (17-19). 
 
PNPLA3 is a lipid droplet protein that is thought to facilitate transacylation of polyunsaturated fatty 
acids (PUFAs) from TGs or diacylglycerols (DAGs) to phosphatidylcholines (PCs) (20,21). In the human 
liver, PNPLA3-I148M confers a similar phenotype as in mice expressing the catalytically inactive 
PNPLA3-S47A variant (20,21), causing retention of PUFAs in IHTGs, with a concomitant deficiency of 
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PUFAs in hepatic PCs and in circulating VLDL (21). Since PUFA-PCs are required for successful 
lipidation of VLDL particles in the liver (22), PNPLA3-I148M could be predicted to decrease plasma 
TG concentrations by reducing the mobilization of fatty acids from IHTGs, or by impairing VLDL 
lipidation via deficiency of PUFA-PCs. However, contrary to expectations, studies which have 
examined the association between PNPLA3-I148M and circulating lipoproteins have not shown the 
variant to induce changes in lipids or lipoproteins (23,24). In a population-based study with 1,810 
individuals aged 34-49 years, the PNPLA3-I148M variant had no effect on plasma lipoproteins (23). 
Another study, which examined lipoprotein compositions in 170 patients with NAFLD, found no 
associations between I148M variant carrier status and concentrations of lipoprotein particles (24). 
 
The degree to which PNPLA3-I148M increases IHTG content is greatly amplified by adiposity (25) and, 
perhaps even more so, by IR (16,26). In normal-weight/insulin-sensitive individuals, the I148M variant 
induces only a negligible increase in IHTGs (16,26). This raises the possibility that IR may be required 
to unmask antiatherogenic effects of PNPLA3-I148M on circulating lipids and lipoproteins. This 
hypothesis was tested in the present study. To this end, we studied the impact of the PNPLA3-I148M 
gene variant and IR on plasma lipids and lipoproteins using nuclear magnetic resonance (NMR) -based 
metabolomics in a cohort of 298 severely obese individuals. The results were replicated in a separate 
cohort consisting of 345 individuals who were less obese. For comparison, we also analyzed the 
impact of the TM6SF2-E167K variant on plasma lipids and lipoproteins. 
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MATERIALS AND METHODS 
Patients 
NMR profiling of plasma lipids and lipoprotein particles was performed in two separate cohorts 
comprising a total of 643 patients who fulfilled the inclusion and exclusion criteria (vide infra). Of 
these, 298 patients were morbidly obese and were studied consecutively prior to undergoing 
laparoscopic bariatric surgery at the Helsinki University Hospital (Helsinki, Finland), referred to as the 
Bariatric cohort. The other 345 leaner volunteers did not undergo surgery and are referred to as the 
Non-bariatric cohort. Inclusion criteria included: (i) age 18 to 75 years; (ii) alcohol consumption less 
than 20 g per day for females and less than 30 g per day for males. Exclusion criteria included: (i) 
known acute or chronic diseases other than obesity, type 2 diabetes, NAFLD or hypertension on the 
basis of medical history, physical examination and standard laboratory tests (complete blood counts, 
serum creatinine and electrolyte concentrations); (ii) clinical or biochemical evidence of liver disease 
other than NAFLD, or clinical signs or symptoms of inborn errors of metabolism; (iii) history or current 
use of toxins or drugs associated with hepatic steatosis, (iv) pregnancy or lactation. The study 
protocols were approved by the ethics committee of the Hospital District of Helsinki and Uusimaa 
(Helsinki, Finland). The study was conducted in accordance with the Declaration of Helsinki. Each 
participant provided a written informed consent after being explained the nature and potential risks 
of the study. 
 
Study design 
All patients arrived at the Clinical Research Unit after an overnight fast (a week before surgery for the 
Bariatric cohort). A history and physical examination were performed to review the inclusion and 
exclusion criteria. Weight, height, waist circumference and blood pressure (BP) were measured as 
previously described (27). Blood samples were taken for measurement of plasma lipids and 
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lipoproteins using NMR profiling (vide infra). In addition, blood samples were taken for measurement 
of blood counts, glucose, glycosylated hemoglobin A1C (HbA1c), insulin, non-esterified fatty acids 
(NEFAs), HDL and LDL cholesterol, TG, alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutamyl transferase (GGT) and albumin concentrations, and for genotyping of NAFLD-
associated alleles PNPLA3 rs738409 (14), TM6SF2 rs58542926 (5), MBOAT7 rs641738 (28) and 
HSD17B13 rs72613567 (29) as previously described (16,30-32). The Bariatric cohort underwent a 
wedge biopsy of the liver at the beginning of the laparoscopic bariatric surgery. Histologic analysis of 
the biopsy was performed by the same pathologist (J.A.) using the SAF score (33). The patients in the 
Non-bariatric cohort underwent measurement of their IHTG content using proton magnetic 
resonance spectroscopy (1H-MRS) (vide infra) within a week after the Clinical Research Unit visit. 
 
We analyzed the effects of PNPLA3-I148M and IR on plasma lipid and lipoprotein composition in the 
Bariatric cohort and Non-bariatric cohort separately. To this end, patients in both cohorts were 
divided into subgroups on the basis of their carrier status for the PNPLA3 rs738409 C>G allele 
(“PNPLA3 CC” or “PNPLA3 CG/GG”) and IR as determined by homeostasis model assessment of insulin 
resistance (HOMA-IR), derived by using the formula: HOMA-IR = fS-insulin (mU/L) × fP-glucose 
(mmol/L) / 22.5 (34). The sex-specific median HOMA-IR was used as the cut-off value for dividing the 
patients in both cohorts into two equally sized groups differing with respect to insulin sensitivity. 
Patients with HOMA-IR at or above this cut-off value (Bariatric cohort, males ≥4.20 and females ≥3.04; 
Non-bariatric cohort, males ≥1.97 and females ≥1.66) were assigned to the “High HOMA-IR” group, 
while patients with HOMA-IR below the cut-off value were assigned to the “Low HOMA-IR” group. Of 
importance, the term “Low HOMA-IR” only refers to variation inside the cohort, as in the Bariatric 
cohort most of the patients had HOMA-IR values higher than 95% of the population (35). As we 
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wanted to analyze the effect of IR on plasma lipoproteins separately from effects of the PNPLA3-
I148M variant, patients in the HOMA-IR subgroups all had the CC genotype. 
 
NMR profiling of lipoprotein subclasses and their composition   
A high-throughput NMR platform (AVANCE III 500 MHz and AVANCE III 600 MHz, Bruker, Karlsruhe, 
Germany) was used for the quantification of lipids and lipoproteins from plasma samples (36). These 
included concentrations and sizes of lipoprotein particles as well as concentrations of total lipids, 
TGs, phospholipids, total cholesterol, esterified cholesterol and free cholesterol in 14 lipoprotein 
subclasses, and concentrations of apolipoproteins A1 and B, as described in (36). 
 
The quantified lipoprotein subfractions and average particle diameters are as follows: extremely large 
very-low-density lipoprotein (XXL-VLDL, >75 nm); very large very-low-density lipoprotein (XL-VLDL, 
64.0 nm); large very-low-density lipoprotein (L-VLDL, 53.6 nm); medium very-low-density lipoprotein 
(M-VLDL, 44.5 nm); small very-low-density lipoprotein (S-VLDL, 36.8 nm); very small very-low-density 
lipoprotein (XS-VLDL, 31.3 nm); intermediate-density lipoprotein (IDL, 28.6 nm); large low-density 
lipoprotein (L-LDL, 25.5 nm); medium low-density lipoprotein (M-LDL, 32.0 nm); small low-density 
lipoprotein (S-LDL, 18.7 nm); very large high-density lipoprotein (XL-HDL, 14.3 nm); large high-density 
lipoprotein (L-HDL, 12.1 nm); medium high-density lipoprotein (M-HDL, 10.9 nm); small high-density 
lipoprotein (S-HDL, 8.7 nm) (36). 
 
Measurement of IHTG content by 1H-MRS 
In Non-bariatric cohort patients in whom liver biopsy was not obtained, IHTG content was measured 
by 1H-MRS using the 1.5T MAGNETOM Avantofit magnetic resonance imaging scanner (Siemens 
Healthcare GmbH, Erlangen, Germany) as previously described in detail (27). In brief, magnetic 
 10 
resonance spectra were acquired using a point resolved spectroscopy sequence with a repetition 
time (TR) of 3,000 ms and an echo time (TE) of 20 ms and quantified using jMRUI v5.2 software (37) 
with the AMARES algorithm (38). Resonances of methylene groups in the FA chains and water were 
determined using line-shape fitting with prior knowledge. IHTG content was expressed as a ratio of 
signal from methylene groups to total signal of methylene and water, and converted from signal ratio 
to a weight fraction, applying the methods validated by Longo et al. (39) and Szczepaniak et al. (40). 
 
Other analytical procedures from human samples 
Fasting plasma glucose was measured using the hexokinase method on an autoanalyzer (Roche 
Diagnostics Hitachi 917, Hitachi Ltd., Tokyo, Japan).  Serum insulin concentration was determined by 
time-resolved fluoroimmunoassay using the Insulin Kit (AUTOdelfia, Wallac, Turku, Finland). HbA1c 
was measured with an immunoturbidometric method (Abbott Laboratories) and plasma ALT, AST, 
and GGT activities using photometric International Federation of Clinical Chemistry methods (Abbott 
Laboratories). Plasma TG, total cholesterol, LDL and HDL cholesterol concentrations were measured 
using enzymatic kits and an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd., Tokyo, Japan). 
Plasma NEFAs were measured by using an enzymatic colorimetric assay (NEFA-HR(2); Wako 
Chemicals GmbH, Neuss, Germany) with a Konelab 60i analyzer (Thermo Electron Corporation, 
Vantaa, Finland). Adipo-IR, a surrogate for adipose tissue IR, was calculated using the formula: fS-
insulin (mU/L) × fP-NEFA (mmol/L) (41). Plasma albumin was measured using a photometric method 
on an autoanalyzer (Modular Analytics EVO; Hitachi High-Technologies Corporation, Tokyo, Japan). 
 
Statistical analyses 
Statistical analyses were performed using Microsoft Excel for Mac 16.35 (Microsoft, Redmond, WA), 
GraphPad Prism 8.1.2 for Mac OS X (GraphPad Software, La Jolla, CA), and R version 3.6.0 (R 
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Foundation for Statistical Computing, Vienna, Austria). Missing NMR-metabolomic data were 
imputed by random forest imputation using the R package “missForest” (42,43). None of the 
variables had over 30% missingness. Univariate normality was determined using the Kolmogorov-
Smirnov test. Non-normally distributed variables were log-transformed for analysis and back-
transformed for display. Data are reported in either means ± standard deviations (SD), medians [25th–
75th percentiles], or in numbers (n) and percentages (%). The unpaired Student’s t-test or the Mann-
Whitney U test were used to compare continuous data and the Pearson’s χ2 test was used to compare 
categorical data. For studying of the effects of PNPLA3 rs738409-G and TM6SF2 rs58542926-T alleles 
in HOMA-IR subgroups in the Bariatric cohort, binary logistic regression analysis was used with the 
genotype (carrier vs. non-carrier) as the dependent variable and NMR-quantified measures as 
independent variables. The models were adjusted for age, sex, BMI, and smoking status (± use of 
statins), and results are displayed as odds ratios (OR) [95% confidence intervals] per unit change in 






Clinical characteristics of the HOMA-IR and PNPLA3 genotype subgroups in the Bariatric cohort are 
shown in Table 1. In the whole cohort, mean age was 49±9 years, mean BMI 43.2±6.8 kg/m2, and 
median HOMA-IR 3.36 [2.01-4.92]. Genotype distributions did not deviate from Hardy-Weinberg 
equilibrium. The subgroups were similar with respect to the distribution of NAFLD risk alleles in 
TM6SF2, MBOAT7, and HSD17B13 genes (Table 1). The “High HOMA-IR” group had significantly more 
type 2 diabetes and a higher BMI (44.3±6.2 vs. 40.8±6.1 kg/m2, P<0.001) and waist circumference, 
higher concentrations of serum insulin and higher HOMA-IR, ALT and plasma TGs than the  “Low 
HOMA-IR” group (Table 1). The “High HOMA-IR” group also had higher IHTG content (13 [5-33] vs. 0 
[0-10] %, P<0.001) and SAF score (2.1±2.0 vs. 1.0±1.5, P<0.001), which is a composite histological 
score of steatosis, necroinflammatory activity and fibrosis, as compared to the “Low HOMA-IR” group 
(Table 1). 
 
The PNPLA3 subgroups were similar with respect to age, sex, BMI, plasma glucose, HbA1C, serum 
insulin, HOMA-IR, plasma lipids, liver enzymes, presence of type 2 diabetes, smoking status, and use 
of medications (Table 1). The “PNPLA3 CG/GG” group had higher IHTG content (15 [0-30] vs. 5 [0-20] 
%, P<0.05) and SAF score (2.0±2.0 vs. 1.6±1.9, P<0.05) than the “PNPLA3 CC” group (Table 1). 
 
Opposing effects of IR and PNPLA3-I148M on plasma lipoproteins 
The distribution of serum TG and cholesterol content within plasma lipoprotein subfractions in the 
Bariatric cohort is shown in Figure 1. Comparison of the NMR-composition of plasma lipoprotein 
subclasses between the HOMA-IR groups in the Bariatric cohort is shown in Figure 2 (left panel). The 
number of XXL-, XL-, L-, M-, and S-VLDL particles as well as M-LDL particles and their constituents, 
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including total lipids, phospholipids, total cholesterol, cholesterol esters, free cholesterol and 
triglycerides, were significantly higher in the “High HOMA-IR” group than in the “Low HOMA-IR” 
group (Figure 2). Triglycerides were also significantly higher in XS-VLDL and S-HDL particles in the 
“High HOMA-IR” as compared to the “Low HOMA-IR” group (Figure 2). On the contrary, the number 
of M-, L- and XL-HDL particles and their constituents were significantly lower in the “High HOMA-IR” 
group than in the “Low HOMA-IR” group (Figure 2). The mean diameter of VLDL particles (39.83±1.55 
vs. 38.71±1.77 nm, P<0.001) was significantly larger while those of LDL (24.48±0.19 vs. 24.55±0.18 
nm, P<0.001) and HDL particles (9.38±0.12 vs. 9.51±0.18 nm, P<0.001) were significantly smaller in 
the “High HOMA-IR” as compared to the “Low HOMA-IR” group. The apolipoprotein B (apoB) to 
apolipoprotein A-1 (apoA-1) ratio was significantly higher (0.64±0.12 vs. 0.57±0.12, P<0.001) in the 
“High HOMA-IR” as compared to the “Low HOMA-IR” group. 
 
Comparison of lipoprotein subclasses between the “PNPLA3 CC” and “PNPLA3 CG/GG” groups 
yielded unremarkable results (Figure 2, middle panel). This finding is in line with previous reports 
where no changes in lipoprotein subfraction concentrations with regard to carrier status of rs738409-
G were observed (23,24). We next grouped the patients based on homozygosity for the rs738409-G 
allele in PNPLA3 (“PNPLA3 CC” and “PNPLA3 GG”) to test whether two variant alleles are required for 
an effect. The resulting groups were similar with respect to age, sex, BMI, plasma glucose, HbA1C, 
serum insulin, HOMA-IR, liver enzymes, plasma cholesterol concentrations, presence of type 2 
diabetes, use of medications, and smoking status (Table 2). Plasma triglycerides were significantly 
lower (1.12 [1.03–1.34] vs. 1.23 [0.88–1.61] mmol/L, P<0.05) and the SAF score was higher (2.6±2.3 
vs. 1.6±1.9, P<0.05) in the “PNPLA3 GG” group as compared to the “PNPLA3 CC” group (Table 2). 
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Changes in lipoprotein subclasses in the “PNPLA3 GG” as compared to the “PNPLA3 CC” group were 
virtually opposite and comparable in magnitude to those observed in the “High HOMA-IR” versus the 
“Low HOMA-IR” group (Figure 2, right panel). The number of XXL-, XL-, L-, and M-VLDL particles and 
most of their constituents as well as M-LDL particles and their constituents were significantly lower, 
while the number of L-HDL particles and their constituents was significantly higher in the “PNPLA3 
GG” group as compared to the “PNPLA3 CC” group (Figure 2). The mean diameter of VLDL (38.6±1.0 
vs. 39.3±1.8 nm, P<0.05) particles was also significantly smaller while that of LDL (24.59±0.12 vs. 
24.51±0.19 nm, P<0.05) particles was significantly larger in the “PNPLA3 GG” group compared to the 
“PNPLA3 CC” group. The apoB to apoA-1 ratio was significantly lower (0.55±0.09 vs. 0.61±0.12, 
P<0.05) in the “PNPLA3 GG” group as compared to the “PNPLA3 CC” group. 
 
The effect of PNPLA3-I148M on plasma lipoproteins is less pronounced in leaner patients 
We replicated the above analysis in an independent cohort consisting of non-morbidly obese and less 
insulin-resistant patients who did not undergo bariatric surgery (Non-bariatric cohort) using the same 
NMR methodology. At the level of the whole cohort, mean age was 45±14 years, mean BMI 29.7±5.7 
kg/m2, and median HOMA-IR 1.64 [0.92-2.82]. Genotype distributions did not deviate from Hardy-
Weinberg equilibrium. The subgroups were similar with respect to the distribution of NAFLD risk 
alleles in TM6SF2, MBOAT7, and HSD17B13 genes (Table 3). The “High HOMA-IR” group was older 
(46±14 vs. 41±13 years, P<0.01) and had significantly higher BMI (32.5±5 vs. 27.0±4 kg/m2, P<0.001), 
waist circumference, systolic BP, liver enzymes, plasma glucose, HbA1C, serum insulin, NEFA, Adipo-
IR, HOMA-IR, TGs, total and LDL cholesterol, and lower HDL cholesterol concentrations as compared 
to the “Low HOMA-IR” group (Table 3). The “High HOMA-IR” group also had higher IHTG content by 
1H-MRS (5.4 [2.9–10.7] vs. 1.0 [0.4–2.2] %, P<0.001) than the “Low HOMA-IR” group (Table 3). The 
“PNPLA3 CC” and “PNPLA3 GG” groups were similar with respect to age, sex, BMI, plasma glucose, 
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HbA1C, serum insulin, HOMA-IR, NEFA, Adipo-IR, plasma lipids, presence of type 2 diabetes, smoking 
status, and use of medications (Table 3). The “PNPLA3 GG” group had higher ALT and AST levels, and 
higher IHTG content (9.1 [4.3–13.1] vs. 2.7 (0.8 – 6.1) %, P<0.001) as compared to the “PNPLA3 CC” 
group (Table 3). 
 
The distribution of serum TG and cholesterol content within plasma lipoprotein subfractions in the 
Non-bariatric cohort is shown in Figure 3. Similar to results in the Bariatric cohort (Figure 2), the “High 
HOMA-IR” group in the Non-bariatric cohort had significantly higher concentrations of all subclasses 
of VLDL, IDL and LDL particles and most of their lipid constituents, and lower concentrations M-, L- 
and XL-HDL particles and their constituents, as compared to the “Low HOMA-IR” group (Figure 4, left 
panel). Differences in lipid profiles between the “High HOMA-IR” and “Low HOMA-IR” groups 
persisted after adjusting for age (data not shown). Like in the Bariatric cohort, we did not find 
significant differences in circulating lipoproteins between the “PNPLA3 CG/GG” and “PNPLA3 GG” 
groups (not shown). However, after excluding heterozygous variant carriers (n=143), the “PNPLA3 
GG” group had significantly lower concentrations of XXL- and XL-VLDL particles and their 
constituents, as well as lower TG content in S-LDL particles, as compared to the “PNPLA3 CC” group 
(Figure 4, right panel). The “PNPLA3 GG” group had also a significantly smaller diameter of VLDL 
(38.6±1.1 vs. 39.1±1.9 nm, P<0.05) particles and a significantly larger diameter of LDL (24.64±0.12 vs. 
24.57±0.20 nm, P<0.01) particles as compared to the “PNPLA3 CC” group. 
 
Insulin resistance amplifies the antihyperlipidemic effect of PNPLA3-I148M, similarly to that of the 
TM6SF2-E167K variant 
The above data suggest that PNPLA3-I148M opposes the effects of severe IR on the number and 
composition of circulating lipoprotein particles, and that this effect is apparent particularly in 
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homozygous carriers of the variant. However, despite similar sample size, the effect of PNPLA3-
I148M on lipoproteins was stronger in the Bariatric cohort (Figure 2) with more severely insulin-
resistant patients than in the Non-bariatric cohort (Figure 4), which consisted of leaner patients. 
 
To determine whether IR interacts with PNPLA3-I148M, we first analyzed the effects of the rs738409-
G allele on lipoproteins by dividing all patients in the Bariatric cohort into two groups based on 
median HOMA-IR (“High HOMA-IR” and “Low HOMA-IR”). We excluded patients on statin therapy 
(n=88) from this analysis. Using a binary logistic regression model adjusted for age, sex, BMI, and 
smoking status, we did not see any significant associations between the rs738409-G allele and 
circulating lipoproteins in the “Low HOMA-IR” group (Figure 5, first panel). On the contrary, in the 
“High HOMA-IR” group, the variant allele predicted significantly lower concentrations of XL-, L-, M-
VLDL and M- and S-LDL particles, higher concentrations of M-, L- and XL-HDL particles, as well as a 
smaller diameter of VLDL particles and larger diameter of HDL particles, higher cholesterol content 
in HDL particles, and higher concentrations of apoA-1 and lower concentrations of apoB 
apolipoproteins (Figure 5, second panel). Thus, high IR appears to be required to unmask the 
antihyperlipidemic effects of PNPLA3-I148M. 
 
For comparison, we analyzed how the TM6SF2-E167K variant interacts with IR in the Bariatric cohort. 
Using a binary logistic regression model adjusted for age, sex, BMI, and smoking status, we did not 
observe any significant associations between the rs58542926-T allele and circulating lipoproteins in 
the “Low HOMA-IR” group (Figure 5, third panel). However, in the “High HOMA-IR” group, the T-allele 
predicted significantly lower concentrations of L-, M-, S-, and XS-VLDL particles, lower TG-content in 
VLDL and LDL particles, and higher concentrations of L-HDL particles (Figure 3, fourth panel). These 
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results resemble those of PNPLA3-I148M and suggest a similar synergistic interaction between the 
TM6SF2-E167K variant and IR. 
 
To determine whether there exists a threshold level of HOMA-IR above which PNPLA3-I148M most 
significantly affects lipids, we next pooled all of the study patients (n=643) and divided them into 
quartiles based on HOMA-IR. Adjusted for age, sex, BMI, smoking status and use of statins, the 
rs738409-G allele did not exert statistically significant changes on lipids in the first three quartiles 
(Figure 6, first three panels). In the highest quartile with HOMA-IR above 3.96 (median 5.50 [4.65-
7.58]), the variant predicted significantly lower concentrations of XL-VLDL, L-VLDL, M-LDL and S-LDL 
particles and a higher concentration of L-HDL particles, lower diameter of VLDL and higher diameter 
of HDL particles, lower TG content in VLDL, lower cholesterol content in LDL, and lower apoB to apoA-




We investigated whether insulin-resistant carriers of the PNPLA3-I148M variant have a less 
atherogenic plasma lipoprotein composition compared to non-carriers, as could be hypothesized 
based on recent mechanistic studies addressing PNPLA3 function (16,20). We found homozygous 
I148M variant carriers to have consistently lower plasma levels of especially VLDL particles and their 
lipid constituents, and higher levels of HDL particles and their constituents, as compared to non-
carriers. The effect of PNPLA3-I148M on lipids and lipoproteins was virtually a mirror-image of the 
typical atherogenic dyslipidemia of insulin-resistant patients. This effect was observed in two 
independent cohorts, which included a Bariatric cohort with morbidly obese individuals and a less 
obese Non-bariatric cohort.  
 
Advances in NMR methodology have resulted in the development of a platform which enables rapid 
and accurate profiling of plasma lipoprotein subclasses and their size and composition, without time- 
and labor-intensive ultracentrifugation techniques (36). This technology allowed us to perform 
comprehensive lipid and lipoprotein profiling in two relatively large independent groups, which were 
both divided into subgroups based on PNPLA3 genotype at rs738409 and sex-specific median HOMA-
IR. A similar approach was previously used to document that the liver lipidome in subjects with NAFLD 
due to the PNPLA3-I148M variant is markedly different from that in subjects with NAFLD due to IR 
(16). The median HOMA-IR of patients in the Bariatric cohort was over 3, which is higher than the 
upper limit of normal of approximately 2 for NAFLD, defined as IHTG content exceeding 5.55% by 1H-
MRS (35,44). Thus, naming of the “Low HOMA-IR” group in this study is a bit of a misnomer. 
 
Despite large patient cohorts, previous studies that have investigated the impact of PNPLA3 
rs738409-G carrier status on plasma lipoprotein composition have produced negative results (23,24). 
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Of note, these studies recruited lean and healthy individuals and lacked the comparison of 
homozygous G-allele carriers to non-carriers. These findings were confirmed in the present study in 
which the PNPLA3-I148M variant had no discernible effect on lipids and lipoproteins in individuals 
classified as “Low HOMA-IR” (Figure 5). Also, the variant appeared to modulate lipids to a smaller 
extent in the less obese Non-bariatric cohort than in the severely obese Bariatric cohort (Figures 2 
and 4), in keeping with data of Palmer et al. in morbidly obese subjects in the Swedish Obese Subjects 
study (45). The dependence of the lipid-altering effects of PNPLA3-I148M on IR is similar to that 
previously described for liver fat, which is most apparent in obese and insulin-resistant homozygous 
carriers (16,25,26). The I148M variant significantly affected lipids only in the highest quartile of 
HOMA-IR, which included subjects with an HOMA-IR greater than 4 in the pooled cohort (Figure 6). 
 
Regarding the mechanism underlying the effect of the PNPLA3-I148M variant on circulating lipids, 
we have previously shown that the human liver of PNPLA3-I148M carriers is deficient in PUFA-PCs 
compared to non-carriers (21). PUFA-PCs are important for lipoprotein formation and stability as they 
form a monolayer around the neutral lipid core consisting of TGs and cholesteryl esters (22). VLDL 
particles are assembled in the endoplasmic reticulum (ER) in hepatocytes, a process beginning with 
translation of apoB on ER-bound ribosomes, which is then lipidated in the ER lumen (22). PCs located 
in the ER membrane are incorporated into nascent VLDL particles, and a deficiency of PC leads to 
premature degradation of VLDL (22). The results of the present study are consistent with relative 
deficiency of hepatic PCs in I148M variant carriers, which could contribute to the reduced hepatic 
VLDL secretion seen in these patients (Figures 2, 4, 5 and 6) (46). 
 
The TM6SF2-E167K variant reduces hepatic VLDL secretion by impairing particle formation and 
lipidation (11,47-49) and is known to induce antiatherogenic changes in plasma lipids and 
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lipoproteins (5-8,23). We compared effects of this variant to that of PNPLA3-I148M (Figure 5). In 
keeping with previous data (5-8,23), TM6SF2-E167K was associated with lower VLDL particle 
concentrations and TGs in VLDL and LDL, and with a trend for lower cholesterol content in these 
lipoproteins as well as for lower apoB concentrations (Figure 5). The E167K variant exerted a 
significant effect in the “High HOMA-IR” but not the “Low HOMA-IR” group (Figure 5). This finding is 
novel for the TM6SF2-E167K variant and resembles the impact of the variant on IHTG content, which 
is amplified by adiposity (25). Consistent with these data, apoB secretion has been found to be 
impaired in variant allele carriers (7,11) and recently in an in vitro disease model using organoids (48). 
Notably, there appears to be a dissociation between human pathology and the Tm6sf2 knock-out 
mouse model, in which particle lipidation is decreased but apoB secretion unchanged (49). 
 
In subjects with IR, both the PNPLA3-I148M and TM6SF2-E167K variants seemed to have an 
approximately equal effect to decrease VLDL particles and VLDL-TG (Figure 5). Consistent with 
previous reports in Europeans and Finns, 39% and 7% of the study participants were hetero- vs. 
homozygous carriers of the PNPLA3-I148M variant, and 13% and 1% of the TM6SF2-E167K variant, 
respectively (5,12,14). These data imply that the TG-lowering effect of PNPLA3-I148M is more 
prevalent than that of TM6SF2-E167K. However, whether PNPLA3-I148M and TM6SF2-E167K confer 
an equal antiatherogenic effect is unclear, as the E167K variant regulates intestinal lipoprotein 
metabolism (8,50) in addition to hepatic lipoprotein metabolism, and possibly also alters cholesterol 
metabolism (8,51) in an antiatherogenic fashion. 
 
Of interest, it has recently been shown that rare loss-of-function mutations in the APOB gene confer 
an increased risk for hepatocellular carcinoma (52).  Carriers of these mutations have a decreased 
hepatic production of the functional apoB protein and consequently develop severe hepatic 
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steatosis, low plasma cholesterol concentrations and are markedly protected against atherosclerotic 
CVD (53). Thus, APOB mutations seem to confer similar albeit a more pronounced phenotype 
compared to that caused by the common NAFLD risk alleles in PNPLA3 and TM6SF2, corroborating 
the notion that hepatic lipid retention plays a key role in causing NAFLD and its subsequent 
complications. 
 
We did not exclude patients on lipid lowering therapies from this study, as dyslipidemias are highly 
prevalent in morbidly obese and insulin-resistant patients. This is an important limitation, as the use 
of statins may affect NMR analysis of circulating lipids. There were no significant differences in the 
use of statins between the patient subgroups. Moreover, the effect of genetic variants on 
lipoproteins was apparent even after excluding statin users in the HOMA-IR subgroup analysis (Figure 
5). 
 
The finding that silencing of PNPLA3 expression ameliorates steatosis in rodents has prompted the 
development of pharmaceuticals aimed at reducing levels of PNPLA3 in the liver (54-56). As PNPLA3-
I148M may in fact be protective against CVD in insulin-resistant patients with NAFLD – who 
presumably would be the main candidates for novel therapeutics – the question arises whether 
blocking of the protein entirely could result in augmented hepatic VLDL secretion, leading to 
increased levels of circulating lipoproteins and worsening or onset of atherogenic dyslipidemia. Given 
that such therapies eventually progress to prospective clinical trials, it should be closely monitored 
whether this happens and if the effect on lipids is transient of permanent. 
 
The emerging evidence that common genetic risk factors, especially the PNPLA3 and TM6SF2 
variants, dissociate liver and cardiovascular outcomes may have implications for guidelines and the 
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clinic. At present, genotyping of the PNPLA3-I148M and TM6SF2-E167K variants is only 
recommended in selected patients and in clinical studies (57). Measurement of HOMA-IR is not 
systematically recommended but could help in identifying those at risk of progressive liver disease 
(57). The present data show that insulin-resistant carriers of the PNPLA3-I148M variant may have 
much better lipid profiles than would be anticipated based on IR alone. Therefore, for example in 
tertiary centers treating morbidly obese patients, genotyping of these variants might prove useful in 
distinguishing those who need closer liver-related follow-up from those in whom more aggressive 
treatment of cardiovascular risk factors is required. Alternatively, lack of atherogenic dyslipidemia in 
routinely assessed lipids in an insulin-resistant patient may be a hint of a greater risk of liver disease, 
especially in cases where HOMA-IR is above 4 which we demonstrated to be the threshold-level for 
PNPLA3-I148M effect. This finding underlines the future challenges of personalized medicine, as 
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Figure 1. Lipoprotein TG and cholesterol composition in the Bariatric cohort. Absolute concentrations 
of TGs (upper panel) and cholesterol (lower panel) in plasma lipoprotein subfractions. Bars represent 
medians, error bars show 25th to 75th percentiles. XXL=extremely large, XL=very large, L=large, 
M=medium, S=small, XS=very small, VLDL=very-low-density lipoprotein, LDL=low-density lipoprotein, 
IDL=intermediate-density lipoprotein, HDL=high-density lipoprotein. 
 
Figure 2. Effects of IR and the PNPLA3 rs738409-G allele on circulating lipoproteins in the Bariatric 
cohort. Differences in absolute concentrations of plasma lipoprotein particle subfractions and their 
lipid constituents between the groups (“High HOMA-IR” vs. “Low HOMA-IR”, panel on the left; 
“PNPLA3 CG/GG” vs. “PNPLA3 CC”, panel in the middle; “PNPLA3 GG” vs. “PNPLA3 CC”, panel on the 
right). Color coding represents the fold change in mean concentrations between the groups. The 
brighter the red color, the higher the increase in the absolute concentration of a lipoprotein fraction 
in the “High HOMA-IR” compared to the “Low HOMA-IR” group, “PNPLA3 CG/GG” compared to the 
“PNPLA3 CC” group, or the “PNPLA3 GG” compared to the “PNPLA3 CC” group. *P≤0.05, **P≤0.01, 
***P≤0.001. XXL=extremely large, XL=very large, L=large, M=medium, S=small, XS=very small, 
VLDL=very-low-density lipoprotein, LDL=low-density lipoprotein, IDL=intermediate-density 
lipoprotein, HDL=high-density lipoprotein. 
 
Figure 3. Lipoprotein TG and cholesterol composition in the Non-bariatric cohort. Absolute 
concentrations of TGs (upper panel) and cholesterol (lower panel) in plasma lipoprotein subfractions. 
Bars represent medians, error bars show 25th to 75th percentiles. XXL=extremely large, XL=very large, 
L=large, M=medium, S=small, XS=very small, VLDL=very-low-density lipoprotein, LDL=low-density 
lipoprotein, IDL=intermediate-density lipoprotein, HDL=high-density lipoprotein. 
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Figure 4. Effects of IR and the PNPLA3 rs738409-G allele on circulating lipoproteins in the Non-bariatric 
cohort. Differences in absolute concentrations of plasma lipoprotein particle subfractions and their 
lipid constituents between groups (“High HOMA-IR” vs. “Low HOMA-IR”, panel on the left; “PNPLA3 
GG” vs. “PNPLA3 CC”, panel on the right). Color coding represents the fold change in mean 
concentrations between the groups. The brighter the red color, the higher the increase in the 
absolute concentration of a lipoprotein fraction in the “High HOMA-IR” compared to the “Low 
HOMA-IR” group or the “PNPLA3 GG” compared to the “PNPLA3 CC” group. *P≤0.05, **P≤0.01, 
***P≤0.001. XXL=extremely large, XL=very large, L=large, M=medium, S=small, XS=very small, 
VLDL=very-low-density lipoprotein, LDL=low-density lipoprotein, IDL=intermediate-density 
lipoprotein, HDL=high-density lipoprotein. 
 
Figure 5. Interaction between IR and NAFLD risk alleles on circulating lipoproteins. Forest plots showing 
genetic effects of PNPLA3 rs738409-G (first two panels) and TM6SF2 rs58542926-T (last two panels) 
alleles on circulating lipoprotein concentrations, particle diameters, particle TG content, particle 
cholesterol content, and apolipoprotein concentrations in “High HOMA-IR” and “Low HOMA-IR” 
groups separately, in the Bariatric cohort. The binary logistic regression models were adjusted for 
age, sex, BMI, and smoking status. The x-axis shows the odds ratio per unit change in standard 
deviation (SD) of a measured variable. Black circles denote statistically significant association and 
white circles no association. Whiskers denote 95% confidence intervals (CI). XXL=extremely large, 
XL=very large, L=large, M=medium, S=small, XS=very small, VLDL=very-low-density lipoprotein, 
LDL=low-density lipoprotein, IDL=intermediate-density lipoprotein, HDL=high-density lipoprotein. 
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Figure 6. Effect of PNPLA3 rs738409-G on circulating lipoproteins stratified by HOMA-IR quartiles in the 
pooled cohort. Forest plots showing genetic effects of the PNPLA3 rs738409-G allele on circulating 
lipoprotein concentrations, particle diameters, particle TG content, particle cholesterol content, and 
apoB to apoA-1 ratio in the pooled cohort, stratified by HOMA-IR quartiles (Q1-Q4). Median HOMA-
IR [25th-75th percentiles] for each quartile are shown. The binary logistic regression models were 
adjusted for age, sex, BMI, smoking status, and use of statins. The x-axis shows the odds ratio per 
unit change in standard deviation (SD) of a measured variable. Black circles denote statistically 
significant association and white circles no association. Whiskers denote 95% confidence intervals 
(CI). XXL=extremely large, XL=very large, L=large, M=medium, S=small, XS=very small, VLDL=very-low-






Table 1. Clinical characteristics of patients in the Bariatric cohort according to sex-specific median HOMA-IR and PNPLA3 
rs738409-G allele carrier status. 
 Low HOMA-IR High HOMA-IR PNPLA3 CC PNPLA3 CG/GG 
Group size, n 86 88 174 124 
Age, years 48 ± 9 48 ± 9 48 ± 9 49 ± 9 
Females, n (%) 65 (76) 65 (74) 130 (75) 87 (70) 
BMI, kg/m2 40.8 ± 6.1 44.3 ± 6.2*** 42.6 ± 6.4 44.0 ± 7.4 
Waist circumference, cm 119 ± 15 130 ± 15*** 125 ± 16 128 ± 17 
Systolic blood pressure, mmHg 132 ± 16 134 ± 16 133 ± 16 135 ± 15 
Diastolic blood pressure, mmHg 84 ± 10 87 ± 9 86 ± 10 88 ± 12 
fP-Glucose, mmol/L 5.4 (5.0–5.9) 6.1 (5.6–6.9)*** 5.8 (5.2–6.3) 5.9 (5.4–6.5) 
HbA1C, % 5.6 (5.4–5.8) 5.9 (5.6–6.4)*** 5.7 (5.4–6.2) 5.8 (5.5–6.2) 
fS-Insulin, mU/L 7.8 (5.8–10.5) 18.2 (14.4–26.3)*** 12.2 (7.7–18.9) 12.8 (8.4–17.9) 
HOMA-IR 1.9 (1.3–2.6) 4.9 (3.9–7.0)*** 3.2 (1.9–4.9) 3.5 (2.2–5.0) 
fP-Total cholesterol, mmol/L 4.2 (3.5–4.8) 4.2 (3.7–4.9) 4.2 (3.6–4.9) 4.2 (3.7–4.8) 
fP-HDL cholesterol, mmol/L 1.27 (1.02–1.50) 1.08 (0.93–1.24)*** 1.14 (0.96–1.38) 1.19 (0.97–1.43) 
fP-LDL cholesterol, mmol/L 2.5 (2.0–3.1) 2.5 (1.9–3.3) 2.5 (2.0–3.2) 2.5 (1.9–3.0) 
fP-Triglycerides, mmol/L 1.02 (0.77–1.28) 1.40 (1.19–1.85)*** 1.23 (0.88–1.61) 1.25 (1.00–1.67) 
P-ALT, U/L 28 (20–39) 38 (25–50)** 31 (23–47) 34 (22–46) 
P-AST, U/L 26 (23–35) 31 (25–36) 28 (23–36) 30 (24–38) 
P-GGT, U/L 25 (17–43) 33 (21–55)** 28 (19–50) 33 (21–49) 
P-Albumin, g/L 38 (37–40) 39 (37–41) 38 (37–41) 38 (36–40) 
B-Platelets, 109/L 239 ± 59 270 ± 58*** 255 (60) 255 (65) 
IHTG (histology), % 0 (0–10) 13 (5–33)*** 5 (0–20) 15 (0–30)* 
NASH, n (%) 6 (7) 14 (17) 14 (8) 18 (15) 
SAF score 1.0 ± 1.5 2.1 ± 2.0*** 1.6 ± 1.9 2.0 ± 2.0* 
Type 2 diabetes, n (%) 23 (27) 38 (43)* 64 (37) 57 (46) 
Current cigarette smoking, n (%) 17 (20) 15 (17) 32 (18) 24 (19) 
Use of antihypertensives, n (%) 50 (58) 57 (65) 107 (61) 82 (66) 
Use of statins, n (%) 22 (26) 31 (35) 53 (30) 35 (28) 
Use of thiazolidinediones, n (%) 3 (3) 3 (3) 6 (3) 7 (6) 
PNPLA3 (CC/CG/GG), n 86/0/0 88/0/0 174/0/0 0/107/17*** 
TM6SF2 (CC/CT/TT), n 76/10/0 77/9/1 153/19/1 108/15/1 
MBOAT7 (CC/CT/TT), n 27/44/14 27/39/19 54/83/33 40/64/20 
HSD17B13 (00/A0/AA), n 47/33/4 58/24/3 105/57/7 74/47/3 
Data are in n (%), mean ± SD or median (25th–75th percentiles). Significances were determined by Student’s t, Mann-Whitney U, 
Chi-squared or Fisher’s exact tests. f, fasting; P, plasma; B, blood; IHTG, intrahepatic triglycerides. *P≤0.05, **P≤0.01, 
***P≤0.001 
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Table 2. Clinical characteristics of homozygous carriers and non-carriers of the PNPLA3 
rs738409-G allele in the Bariatric cohort. 
 PNPLA3 CC PNPLA3 GG 
Group size, n 174 17 
Age, years 48 ± 9 46 ± 9 
Females, n (%) 130 (75) 12 (71) 
BMI, kg/m2 42.6 ± 6.4 41.9 ± 11.5 
Waist circumference, cm 124.9 ± 15.7 122.4 ± 23.3 
Systolic blood pressure, mmHg 133 ± 16 136 ± 15 
Diastolic blood pressure, mmHg 86 ± 9 91 ± 12 
fP-Glucose, mmol/L 5.8 (5.2–6.3) 5.6 (5.0–6.0) 
HbA1C, % 5.7 (5.4–6.2) 5.7 (5.5–6.0) 
fS-Insulin, mU/L 12.2 (7.7–18.9) 12.4 (6.0–22.0) 
HOMA-IR 3.2 (1.9–4.5) 3.0 (1.5–5.3) 
fP-Total cholesterol, mmol/L 4.2 (3.6–4.9) 4.3 (3.6–4.8) 
fP-HDL cholesterol, mmol/L 1.14 (0.96–1.38) 1.23 (1.09–1.61) 
fP-LDL cholesterol, mmol/L 2.5 (2.0–3.2) 2.3 (2.0–3.0) 
fP-Triglycerides, mmol/L 1.23 (0.88–1.61) 1.12 (1.03–1.34)* 
P-ALT, U/L 31 (23–47) 35 (22–48) 
P-AST, U/L 28 (23–36) 34 (27–50) 
P-GGT, U/L 28 (19–50) 22 (19–56) 
P-Albumin, g/L 38 (37–41) 38 (36–39) 
B-Platelets, 109/L 255 ± 60 230 ± 67 
IHTG (histology), % 5 (0–20) 15 (5–20) 
NASH, n (%) 14 (8) 3 (18) 
SAF score 1.6 ± 1.9 2.6 ± 2.3* 
Type 2 diabetes, n (%) 61 (35) 7 (41) 
Current cigarette smoking, n (%) 32 (18) 4 (24) 
Use of antihypertensives, n (%) 107 (61) 10 (59) 
Use of statins, n (%) 53 (30) 4 (24) 
Use of thiazolidinediones, n (%) 6 (3) 0 (0) 
PNPLA3 (CC/CG/GG), n 174/0/0 0/0/17*** 
TM6SF2 (CC/CT/TT), n 153/19/1 14/3/0 
MBOAT7 (CC/CT/TT), n 54/83/33 3/13/1 
HSD17B13 (00/A0/AA), n 105/57/7 13/4/0 
Data are in n (%), mean ± SD or median (25th-75th percentiles). Significances were 
determined by Student’s t, Mann-Whitney U, Chi-squared or Fisher’s exact tests. f, 






Table 3. Clinical characteristics of volunteers in the Non-bariatric cohort according to sex-specific HOMA-IR and PNPLA3 rs738409-G 
allele carrier status. 
 Low HOMA-IR High HOMA-IR PNPLA3 CC PNPLA3 GG 
Group size, n 88 89 177 25 
Age, years 41 ± 13 46 ± 14** 43 ± 14 47 ± 14 
Females, n (%) 50 (57) 51 (57) 101 (57) 17 (68) 
BMI, kg/m2 27.0 ± 4 32.5 ± 5*** 29.8 ± 5.2 31.3 ± 7.2 
Waist circumference, cm 90.3 ± 10.9 106.4 ± 11.0*** 98.4 ± 13.6 102.2 ± 16.6 
Systolic blood pressure, mmHg 129 ± 19 135 ± 19* 132 ± 19 131 ± 22 
Diastolic blood pressure, mmHg 82 ± 14 85 ± 11 83 ± 13 86 ± 10 
fP-Glucose, mmol/L 5.3 (5.0–5.6) 5.8 (5.5–6.2)*** 5.6 (5.1–6.0) 5.7 (5.1–5.9) 
HbA1C, % 5.4 (5.3–5.6) 5.8 (5.6–6.1)*** 5.6 (5.4–5.9) 5.7 (5.3–5.9) 
fS-Insulin, mU/L 3.9 (3.0–5.7) 11.1 (9.0–14.5)*** 7.0 (3.9–11.1) 6.5 (5.0–10.3) 
HOMA-IR 0.9 (0.7–1.4) 2.9 (2.3–3.9)*** 1.8 (0.9–2.9) 1.6 (1.2–2.6) 
fP-NEFA, umol/L 415 (321–568) 579 (433–734)*** 491 (375–667) 556 (412–600) 
Adipo-IR 1611 (1169–2872) 6666 (4661–9605)*** 3198 (1590–5875) 3314 (1908–5092) 
fP-Total cholesterol, mmol/L 4.5 (4.0–5.0) 4.9 (4.5–5.6)*** 4.7 (4.2–5.3) 5.1 (4.2–5.6) 
fP-HDL cholesterol, mmol/L 1.54 (1.29–1.72) 1.27 (1.09–1.49)*** 1.38 (1.18–1.66) 1.40 (1.23–1.72) 
fP-LDL cholesterol, mmol/L 2.6 (2.2–3.1) 3.1 (2.6–3.6)*** 2.80 (2.30–3.40) 3.0 (2.1–3.5) 
fP-Triglycerides, mmol/L 0.84 (0.61–1.19) 1.55 (1.22–2.07)*** 1.20 (0.78–1.64) 1.22 (0.96–1.50) 
P-ALT, U/L 20 (16–28) 33 (23–51)*** 25.50 (18–38) 41 (23–79)** 
P-AST, U/L 25 (22–30) 28 (24–35)** 26 (22–32) 39 (28–53)*** 
P-GGT, U/L 18 (13–28) 36 (19–62)*** 23 (15–43) 27 (20–59) 
P-Albumin, g/L 38 (36–40) 39 (37–41) 39.10 (36.20–40.42) 38 (36–40) 
B-Platelets, 109/L 234 (209–261) 246 (203–282) 236 (207–278) 240 (214–268) 
IHTG (1H-MRS), % 1.0 (0.4–2.2) 5.4 (2.9–10.7)*** 2.7 (0.8 – 6.1) 9.1 (4.3–13.1)*** 
Type 2 diabetes, n (%) 4 (5) 12 (13) 16 (9) 2 (8) 
Current cigarette smoking, n (%) 21 (24) 14 (16) 35 (20) 6 (24) 
Use of antihypertensives, n (%) 12 (14) 27 (30)** 39 (22) 7 (28) 
Use of statins, n (%) 8 (9) 12 (13) 20 (11) 5 (20) 
Use of thiazolidinediones, n (%) 0 (0) 1 (1) 1 (1) 1 (4) 
PNPLA3 (CC/CG/GG), n 88/0/0 89/0/0 177/0/0 0/0/25*** 
TM6SF2 (CC/CT/TT), n 75/11/1 76/9/1 151/20/2 18/6/0 
MBOAT7 (CC/CT/TT), n 33/35/14 30/40/10 63/75/24 6/12/4 
HSD17B13 (00/A0/AA), n 45/18/4 47/20/4 92/38/8 11/9/0 
Data are in n (%), mean ± SD or median (25th-75th percentiles). Significances were determined by Student’s t, Mann-Whitney U, Chi-
squared or Fisher’s exact tests. f, fasting; P, plasma; B, blood; IHTG, intrahepatic triglycerides; 1H-MRS, proton magnetic resonance 
spectroscopy. *P≤0.05, **P≤0.01, ***P≤0.001 
 41 
FIGURES 
 
FIGURE 1 
 
  
X
X
L-
V
LD
L
X
L-
V
LD
L
L-
V
LD
L
M
-V
LD
L
S
-V
LD
L
X
S
-V
LD
L
ID
L
L-
LD
L
M
-L
D
L
S
-L
D
L
S
-H
D
L
M
-H
D
L
L-
H
D
L
X
L-
H
D
L
0.0
0.1
0.2
0.3
0.4
T
ri
g
ly
c
e
ri
d
e
 (
m
m
o
l/L
)
X
X
L-
V
LD
L
X
L-
V
LD
L
L-
V
LD
L
M
-V
LD
L
S
-V
LD
L
X
S
-V
LD
L
ID
L
L-
LD
L
M
-L
D
L
S
-L
D
L
S
-H
D
L
M
-H
D
L
L-
H
D
L
X
L-
H
D
L
0.0
0.3
0.6
0.9
1.2
1.5
C
h
o
le
s
te
ro
l 
(m
m
o
l/L
)
 42 
FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
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FIGURE 6 
 
